Note: before purchasing and taking medicines, a hospital genetic test report and a doctor's diagnosis report or certificate must be produced
1. Hepatocellular carcinoma: a treatment used to treat patients with unresectable hepatocellular carcinoma (HCC).
2. Renal cell carcinoma: treatment for patients with advanced renal cell carcinoma (RCC).
3. Differentiated thyroid cancer: for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid cancer (DTC) refractory to radioiodine therapy.
Recommended doses for hepatocellular carcinoma, renal cell carcinoma and differentiated thyroid carcinoma:
The recommended daily dose is 400 mg (2 x 200 mg tablets), 200 mg twice daily, at least 1 hour before meals or 2 hours after meals. Treatment should continue until patients no longer clinically benefit from treatment or experience unacceptable toxicity.
Studies have shown that sorafenib causes relatively few side effects to patients, and patients taking sorafenib and those not taking sorafenib in the study presented with a variety of symptoms that were relatively close, thereby inferring that many symptoms may be caused by liver cancer itself.
Side effects that have the potential to be caused by the drug include: hand foot syndrome (dysesthesia or erythema of the hands and feet), diarrhea, alopecia, fatigue, hypertension, anorexia, as well as nausea. The side effects of sorafenib are not serious, but they also need attention. Special attention should be paid to protect liver function and cholestasis, and some drugs can be used simultaneously.